Neurology News with information about conditions, treatments, current studies and breakthroughs.
Lumbar Radiculopathies
What are lumbar radiculopathies? Lumbar radiculopathies refer to conditions that cause pain, numbness, or weakness in the legs due to [...]
Thoracic Radiculopathies
What are thoracic radiculopathies? Thoracic radiculopathies refer to conditions that cause pain, weakness, or numbness in the chest, abdomen, and [...]
Cervical Radiculopathy
What is cervical radiculopathy? Cervical radiculopathy is a condition that occurs when a nerve in the neck is compressed or [...]
Speech Therapist
What is a speech therapist? A speech therapist, also known as a speech-language pathologist, is a healthcare professional who specializes [...]
Physical Therapist
What is a physical therapist? A physical therapist is a healthcare professional who helps patients recover from injuries, manage chronic [...]
Myopathy
What is myopathy? Myopathy is a medical term that refers to a group of diseases that affect the muscle fibers [...]
- Exposure to Air Pollutants and Lewy Body and Parkinson Disease–Related Dementias June 12, 2026New JAMA Publication! Congratulations to Dimitry S. Davydow, MD, MPH, Gregory M. Pontone, MD, MHS, Michael S. Okun, MD, and Melissa J. Armstrong, MD on their publication “Exposure to Air Pollutants and Lewy Body and Parkinson Disease–Related Dementias,” which appears in JAMA Open Network. Long-term exposure to common air pollutants may increase the risk of developing Parkinson’s disease-related dementia and Lewy body dementia, according to…
- Real-World Safety and Effectiveness of 24-Hour Foslevodopa/Foscarbidopa in Parkinson’s Disease: ROSSINI Study 6-Month Interim Results June 10, 2026Congratulations Dr. Irene Malaty Dr. Malaty research “Real-World Safety and Effectiveness of 24-Hour Foslevodopa/Foscarbidopa in Parkinson’s Disease: ROSSINI Study 6-Month Interim Results,” was published in the May 2026 issue of Neurology and Therapy. Abstract Foslevodopa/foscarbidopa (LDp/CDp) is a nonsurgical 24-h continuous subcutaneous infusion for patients with advanced Parkinson’s disease (aPD) and motor fluctuations uncontrolled on…
- Diffusion MRI and α‐Synuclein Seed Amplification Status in Parkinson’s Disease June 8, 2026New Publication! Congratulations to Drs. Melissa J Armstrong, Nikolaus R. McFarland, Michael Okun and David Vaillancourt on the publication of “Diffusion MRI and α‐Synuclein Seed Amplification Status in Parkinson’s Disease,” which appears in the May edition of Annals of Neurology. Abstract Objective Positive α‐synuclein seed amplification assay (SAA) is a biomarker found in most people…
- Unveiling Reporting & Representation of Race and Ethnicity in Acute Interventional Neurology Trials: A Systematic Review June 5, 2026Congratulations on your new publication! Congratulations to Hector David Meza Comparan, Luciola Frota, Michael Mathelier, Carolina Maciel and Katharina Busl on the publication of “Unveiling Reporting & Representation of Race and Ethnicity in Acute Interventional Neurology Trials: A Systematic Review,” which appears in the April 8th edition of Neurology. Abstract Objective: To evaluate the extent and…
Get Social